Content about Chilcott

January 9, 2014

Amneal Pharmaceuticals has appointed Rochelle Fuhrmann as CFO, the generic drug maker said Thursday.

BRIDGEWATER, N.J. — Amneal Pharmaceuticals has appointed Rochelle Fuhrmann as CFO, the generic drug maker said Thursday.

Fuhrmann was formerly SVP finance at Warner Chilcott, where she was responsible for the oversight and direction of the finance and accounting functions, including corporate accounting, financial planning and analysis, tax, treasury, risk management, internal audit and investor relations. She began working at Warner Chilcott in June 2006 and was promoted to SVP in January 2011.

December 11, 2013

A subsidiary of Actavis has reached a settlement with a generic drug maker that will allow the launch of a generic version of a treatment for ulcerative colitis in 2015.

DUBLIN — A subsidiary of Actavis has reached a settlement with a generic drug maker that will allow the launch of a generic version of a treatment for ulcerative colitis in 2015.

Actavis said its Warner Chilcott subsidiary had settled with Zydus Pharmaceuticals USA and Cadila Healthcare over Zydus' generic version of Asacol HD (mesalamine) delayed-release tablets.

November 21, 2013

Actavis will lay off more than 30% of the sales staff from its branded-drugs division as part of its acquisition of Warner Chilcott, the drug maker said.

DUBLIN — Actavis will lay off more than 30% of the sales staff from its branded-drugs division as part of its acquisition of Warner Chilcott, the drug maker said.

October 2, 2013

Actavis has appointed the board of directors for the division it recently created as part of its acquisition of Ireland-based Warner Chilcott, the drug maker said.

DUBLIN — Actavis has appointed the board of directors for the division it recently created as part of its acquisition of Ireland-based Warner Chilcott, the drug maker said.

Actavis, which announced the $8.5 billion purchase of Warner Chilcott, cleared the final regulatory hurdle to the acquisition Monday when the Irish High Court approved it. As part of the acquisition, it is changing Warner Chilcott's name to Actavis plc.

October 1, 2013

Ireland's High Court has approved Actavis' acquisition of Warner Chilcott, the drug makers said.

DUBLIN — Ireland's High Court has approved Actavis' acquisition of Warner Chilcott, the drug makers said.

The companies said the approval of Irish authorities meant that they had obtained all regulatory approvals required to complete the transaction, and that it now remained subject to satisfaction of other customary closing conditions and would occur as soon as practicable.

Actavis and Warner Chilcott announced the $8.5 billion merger deal in May. The companies' shareholders voted to approve it on Sept. 10.

 

September 10, 2013

Shareholders of Actavis and Warner Chilcott have approved the merger of the two drug makers, the companies said Tuesday.

PARSIPPANY, N.J. — Shareholders of Actavis and Warner Chilcott have approved the merger of the two drug makers, the companies said Tuesday.

The deal, whereby U.S.-based Actavis will acquire Ireland-based Warner Chilcott, is expected to close later this year.

August 29, 2013

Three independent proxy advisory firms are recommending that Actavis shareholders vote in favor of the company's proposed acquisition of Warner Chilcott.

PARSIPPANY, N.J. — Three independent proxy advisory firms are recommending that Actavis shareholders vote in favor of the company's proposed acquisition of Warner Chilcott.

Actavis said Thursday that Institutional Shareholder Services, Glass Lewis and Egan-Jones had issued the recommendation regarding the $8.5 billion acquisition of Ireland-based Warner Chilcott, announced in May.

August 9, 2013

Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said.

 PARSIPPANY, N.J. — Actavis and Warner Chilcott have received approval from all necessary antitrust clearances for their merger from regulators outside the United States, the companies said Friday.

The drug makers said that the French Competition Authority had approved U.S.-based Actavis' acquisition of Ireland-based Warner Chilcott. The German Federal Cartel Office had previously approved the deal as well.

July 11, 2013

Actavis and Warner Chilcott announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott.

PARSIPPANY, N.J. — Actavis and Warner Chilcott on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Warner Chilcott. The information request was issued under notification requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.  

May 20, 2013

Actavis will acquire Warner Chilcott for $8.5 billion, the drug maker said.

PARSIPPANY, N.J. — Actavis will acquire Warner Chilcott for $8.5 billion, the drug maker said Monday.

May 14, 2013

Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland's merger-and-acquisition rules.

PARSIPPANY, N.J. — Actavis is continuing to pursue a plan to buy Irish drug maker Warner Chilcott, as the U.S.-based company announced Tuesday its total number of shares and share-purchase options in order to comply with Ireland's merger-and-acquisition rules.

Actavis listed about 133.3 million ordinary shares, 1.5 billion restricted shares and 1.26 options to purchase ordinary shares.

May 10, 2013

Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said.

PARSIPPANY, N.J. — Actavis is looking into the possibility of buying Warner Chilcott, the generic drug maker said Friday.

Actavis, the world's third-largest generic drug maker, said it had entered into early-stage discussions with Warner Chilcott about a potential combination of the two, but that no agreement had been reached, and that it wouldn't issue further comment about the matter.

April 23, 2013

The Food and Drug Administration has approved a new contraceptive drug made by Warner Chilcott, the drug maker said.

DUBLIN — The Food and Drug Administration has approved a new contraceptive drug made by Warner Chilcott, the drug maker said.

Warner Chilcott announced the approval of Minastrin 24 FE (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules) for prevention of pregnancy.

The drug maker said an unnamed third-party company would manufacture the drug, but it did not expect to launch it this year.

 

April 16, 2013

The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

DUBLIN — The Food and Drug Administration has approved a new strength of an antibiotic made by Warner Chilcott, the drug maker said.

Warner Chilcott announced the approval of the 200-mg strength of Doryx (doxycycline hyalite) delayed-release tablets, which the company plans to release in July 2013.

Doryx delayed-release tablets are already available in the 75-mg, 100-mg and 150-mg strengths.

 

February 8, 2013

The Food and Drug Administration has approved a new drug from Warner Chilcott for treating ulcerative colitis, the drug maker said.

DUBLIN — The Food and Drug Administration has approved a new drug from Warner Chilcott for treating ulcerative colitis, the drug maker said.

Warner Chilcott announced the approval of mesalamine in the 400-mg strength.

The company plans to market the drug under the brand name Delzicol and launch it in March.